Dr Yves Fradet graduated from Laval University (Quebec, Canada) in 1981 and completed an oncology fellowship at the Memorial Sloan-Kettering Cancer Center, with Drs Willet Whitmore and Lloyd Old. In 1983 he founded, at the Laval University Cancer Research Center, a translational and clinical research laboratory  in urological cancers whose work are supported continuously for more than 30 years.

Dr Fradet still has a very active practice in uro-Oncology within the Urologic Oncology Section and the Urology Service at the CHU de Québec- Hôtel-Dieu de Québec where he has grouped a team of specialists among the most important in Canada including seven uro-oncologists, three of which are also holders of PhD.

He is a member of many national and international societies, including since 2001, the American Association of Genitourinary Surgeons in which he was invited to be part of the 75 members in America. More recently, he was appointed international honorary member of the Association of Academic European Urology, membership awarded to those who have had important influence on urology. Dr Fradet is often invited as a guest speaker at national and international meetings, as a visiting professor, and as a consultant to many organizations. He was the founding chairman of the Canadian Urologic Oncology Group from 1988 to 1995 and chairman of the Department of Surgery at Laval University from 2000 to 2008. He has authored over 330 publications and book chapters and more than 600 abstracts.

Hôpital de l'Enfant-Jésus
1401, 18e rue
G4.610
Québec, QC
Canada G1J 1Z4
+1 418-525-4444, extension 67694+1 418-691-3154
Yves.Fradet@crchudequebec...

Latest news

353 entries « ‹ 1 of 36 › »

Graff JN, Hoimes CJ, Gerritsen WR, Vaishampayan UN, Elliott T, Hwang C, Ten Tije AJ, Omlin A, McDermott RS, Fradet Y, Tagawa ST, Kilari D, Ferrario C, Uemura H, Jones RJ, Fukasawa S, Peer A, Niu C, Poehlein CH, Qiu P, Suttner L, de Wit R, Schloss C, de Bono JS, Antonarakis ES

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Journal Article

Prostate Cancer Prostatic Dis, 2024.

Abstract | Links:

de Wit R, Vaughn DJ, Fradet Y, Fong L, Climent MA, Necchi A, Petrylak DP, Gerritsen WR, Gurney H, Quinn DI, Culine S, Sternberg CN, Bajorin DF, Choueiri TK, Xu J, Imai K, Homet Moreno B, Bellmunt J, Lee JL

Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial

Journal Article

Eur Urol, 2024.

Abstract | Links:

Garneau CA, Marcotte N, Lacombe L, Fradet Y, Fradet V, Pouliot F, Toren P, Lodde M

Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC

Journal Article

Can Urol Assoc J, 18 (2), 2024.

Abstract | Links:

Robitaille K, Guertin MH, Jamshidi A, Xu HW, Hovington H, Pelletier JF, Beaudoin L, Gevariya N, Lacombe L, Tiguert R, Caumartin Y, Dujardin T, Toren P, Lodde M, Racine É, Trudel D, Perigny M, Duchesne T, Savard J, Julien P, Fradet Y, Fradet V

A phase IIb randomized placebo-controlled trial testing the effect of MAG-EPA long-chain omega-3 fatty acid dietary supplement on prostate cancer proliferation

Journal Article

Commun Med (Lond), 4 (1), 2024.

Abstract | Links:

Lachance G, Robitaille K, Laaraj J, Gevariya N, Varin TV, Feldiorean A, Gaignier F, Julien IB, Xu HW, Hallal T, Pelletier JF, Bouslama S, Boufaied N, Derome N, Bergeron A, Ellis L, Piccirillo CA, Raymond F, Fradet Y, Labbé DP, Marette A, Fradet V

The gut microbiome-prostate cancer crosstalk is modulated by dietary polyunsaturated long-chain fatty acids

Journal Article

Nat Commun, 15 (1), 2024.

Abstract | Links:

Lafront C, Germain L, Campolina-Silva GH, Weidmann C, Berthiaume L, Hovington H, Brisson H, Jobin C, Frégeau-Proulx L, Cotau R, Gonthier K, Lacouture A, Caron P, Ménard C, Atallah C, Riopel J, Latulippe É, Bergeron A, Toren P, Guillemette C, Pelletier M, Fradet Y, Belleannée C, Pouliot F, Lacombe L, Lévesque É, Audet-Walsh É

The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression

Journal Article

J Clin Invest, 134 (11), 2024.

Abstract | Links:

Molina OE, LaRue H, Simonyan D, Hovington H, Vittrant B, Têtu B, Fradet V, Lacombe L, Bergeron A, Fradet Y

Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes

Journal Article

Front Immunol, 15 , 2024.

Abstract | Links:

Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Bergeron A, Castonguay V, Couture F, Chevalier S, Brimo F, Fazli L, Fleshner N, Gleave M, Karakiewicz PI, Lattouf JB, Trudel D, van der Kwast T, Mes-Masson AM, Pouliot F, Fradet Y, Audet-Walsh E, Saad F, Guillemette C, Lévesque E

UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways

Journal Article

Cancer Lett, 553 , 2023.

Abstract | Links:

Gonthier K, Weidmann C, Berthiaume L, Jobin C, Lacouture A, Lafront C, Harvey M, Neveu B, Loehr J, Bergeron A, Fradet Y, Lacombe L, Riopel J, Latulippe É, Atallah C, Shum M, Lambert JP, Pouliot F, Pelletier M, Audet-Walsh É

Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer

Journal Article

Mol Oncol, 17 (10), 2023.

Abstract | Links:

Moussa H, Robitaille K, Pelletier JF, Tourigny R, Fradet Y, Lacombe L, Toren P, Lodde M, Tiguert R, Dujardin T, Caumartin Y, Duchesne T, Julien P, Savard J, Diorio C, Fradet V

Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA)

Journal Article

Nutrients, 15 (6), 2023.

Abstract | Links:

353 entries « ‹ 1 of 36 › »
Signaler des ajouts ou des modifications

Active projects

  • Améliorer la réponse aux traitements en cancer de la vessie, from 2024-06-25 to 2026-10-01
  • Developement of a prostate cancer vaccine, from 2022-07-20 to 2025-05-01
  • En route vers de nouvelles avenues thérapeutiques en cancer de la prostate, from 2024-06-25 to 2026-10-01
  • Investigation multi-omiques des effets des acides gras oméga-3 et de la sélénonèine sur des organoïdes dérivés de patients atteints de cancer de la prostate., from 2024-07-02 to 2026-07-30
  • Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma, from 2022-08-01 to 2026-07-31
  • Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
  • What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancer, from 2022-01-15 to 2025-03-31

Recently finished projects

  • CQDM_Projet de recherche PICT-01 sur le cancer de la prostate , from 2019-12-01 to 2022-11-30
  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers, from 2020-06-01 to 2024-04-30
  • Impact of lifestyle on gut barrier function, bacterial translocation and risk of prostate cancer, from 2020-09-01 to 2023-04-30
  • Maintien de colonies de souris transgéniques exprimant des molécules de CMH humaines , from 2022-03-22 to 2023-03-21
Data provided by the Université Laval research projects registery